Advertisement

Is Routine Splenectomy Justified for All Left-Sided Pancreatic Cancers? Histological Reappraisal of Splenic Hilar Lymphadenectomy

  • Maxime Collard
  • Tiziana Marchese
  • Nathalie Guedj
  • François Cauchy
  • Caroline Chassaing
  • Maxime Ronot
  • Safi Dokmak
  • Olivier Soubrane
  • Alain SauvanetEmail author
Pancreatic Tumors
  • 29 Downloads

Abstract

Background

Although splenectomy is recommended during resection for left-sided resectable pancreatic ductal adenocarcinoma (PDAC) to perform lymphadenectomy of station 10 (splenic hilum), no level I evidence justifies this procedure. This study aims to evaluate the rate of lymph node (LN) and contiguous involvement of the splenic hilum in resectable distal PDAC.

Methods

We retrospectively reviewed all patients who underwent splenopancreatectomy for PDAC in the past 10 years. Station 10 LN were routinely isolated, and all corresponding microscopic slides were reinterpreted by a pathologist. The computed tomography (CT) results of patients with tumoral involvement of the spleen or splenic hilum by contiguity (TISOSH) and ≤ 10 mm between the tumor and spleen on pathology were blindly reviewed by two radiologists to evaluate CT for diagnosis of TISOSH.

Results

We included 110 consecutive patients, including 104 with analyzable station 10 LN. The tumor was N+ in 58 (53%) patients. The median number of LN identified at station 10 was 2.0 ± 3.0. No station 10 LNs were detected in 42 (40%) patients. No patients had tumor-positive LN at station 10. TISOSH was found in nine (8%) patients, and was significantly associated with tail location (p = 0.001), tumor size (p = 0.005), and multivisceral involvement (p = 0.015). For diagnosis of TISOSH, the sensitivity and specificity of CT were respectively 89% and 95% for radiologist 1 and 89% and 100% for radiologist 2.

Conclusions

Splenic preservation during resection of distal PDAC may be an option in selected patients with body tumors and no suspected splenic or splenic hilum involvement on preoperative CT.

Notes

Disclosure

None reported.

References

  1. 1.
    Onesti JK, Chung MH, Jain DH, et al. A review of splenic pathology in distal pancreatectomies. Pancreatology. 2013;13:625–8.CrossRefGoogle Scholar
  2. 2.
    Kim SH, Kang CM, Satoi S, et al. Proposal for splenectomy-omitting radical distal pancreatectomy in well-selected left-sided pancreatic cancer: multicenter survey study. J Hepatobiliary Pancreat Sci. 2013;20:375–81.CrossRefGoogle Scholar
  3. 3.
    Sahin TT, Fujii T, Kanda M, et al. Prognostic implications of lymph node metastases in carcinoma of the body and tail of the pancreas. Pancreas. 2011;40:1029–33.CrossRefGoogle Scholar
  4. 4.
    Tsiouris A, Cogan CM, Velanovich V. Distal pancreatectomy with or without splenectomy: comparison of postoperative outcomes and surrogates of splenic function. HPB (Oxford). 2011;13:738–44.CrossRefGoogle Scholar
  5. 5.
    Pendola F, Gadde R, Ripat C, et al. Distal pancreatectomy for benign and low grade malignant tumors: short-term postoperative outcomes of spleen preservation—a systematic review and update meta-analysis. J Surg Oncol. 2017;115:137–43.CrossRefGoogle Scholar
  6. 6.
    Buzelé R, Barbier L, Sauvanet A, Fantin B. Medical complications following splenectomy. J Visc Surg. 2016;153:277–86.CrossRefGoogle Scholar
  7. 7.
    Sinwar PD. Overwhelming post splenectomy infection syndrome—review study. Int J Surg. 2014;12:1314–6.CrossRefGoogle Scholar
  8. 8.
    Anon. Japan Pancreas Society. Classification of Pancreatic Carcinoma (1st English edn.) Kanehara: Tokyo 1996.Google Scholar
  9. 9.
    Washinghton K, Berlin J, Branton P, et al. Protocol for the examination of specimens from patients with carcinoma of the pancreas. Based on AJCC/UICTNM 7th ed. College of American Pathologists 2016.Google Scholar
  10. 10.
    Fujita T, Nakagohri T, Gotohda N, et al. Evaluation of the prognostic factors and significance of lymph node status in invasive ductal carcinoma of the body or tail of the pancreas. Pancreas. 2010;39:e48–54.CrossRefGoogle Scholar
  11. 11.
    Jang JY, Han Y, Lee H, et al. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer a prospective, randomized, open-label, multicenter phase 2/3 trial. Ann Surg. 2018;268:215–22.CrossRefGoogle Scholar
  12. 12.
    Tarantino I, Warschkow R, Hackert T, et al. Staging of pancreatic cancer based on the number of positive lymph nodes. Br J Surg. 2017;104:608–18.CrossRefGoogle Scholar
  13. 13.
    Warschkow R, Widmann B, Beutner U, et al. The more the better-lower rate of stage migration and better survival in patients with retrieval of 20 or more regional lymph nodes in pancreatic cancer: a population-based propensity score matched and trend SEER analysis. Pancreas. 2017;46:648–57.CrossRefGoogle Scholar
  14. 14.
    Lahat G, Lubezky N, Gerstenhaber F, et al. Number of evaluated lymph nodes and positive lymph nodes, lymph node ratio, and log odds evaluation in early-stage pancreatic ductal adenocarcinoma: numerology or valid indicators of patient outcome? World J Surg Oncol. 2016;14:254.CrossRefGoogle Scholar
  15. 15.
    Sano T, Sasako M, Mizusawa J, et al. Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma. Ann Surg. 2017;265:277–83.CrossRefGoogle Scholar
  16. 16.
    Di Sabatino A, Carsetti R, Corazza GR. Post-splenectomy and hyposplenic states. Lancet. 2011;378:86–97.CrossRefGoogle Scholar
  17. 17.
    Holdsworth RJ, Irving AD, Cuschieri A. Postsplenectomy sepsis and its mortality rate: actual versus perceived risks. Br J Surg. 1991;78:1031–8.CrossRefGoogle Scholar
  18. 18.
    Hassenpflug M, Tjaden C, Hinz U, et al. Hypercoagulability after distal pancreatectomy: Just meaningless alterations? Pancreatology. 2017;17:478–83.CrossRefGoogle Scholar
  19. 19.
    Tang CW, Feng WM, Bao Y, et al. Spleen-preserving distal pancreatectomy or distal pancreatectomy with splenectomy? Perioperative and patient-reported outcome analysis. J Clin Gastroenterol. 2014;48:e62–6.CrossRefGoogle Scholar
  20. 20.
    Kashuk JL, Moore EE, Johnson JL et al. Progressive postinjury thrombocytosis is associated with thromboembolic complications. Surgery. 2010;148:667–674. discussion 674–675.CrossRefGoogle Scholar
  21. 21.
    Pimpl W, Dapunt O, Kaindl H, Thalhamer J. Incidence of septic and thromboembolic-related deaths after splenectomy in adults. Br J Surg. 1989;76:517–21.CrossRefGoogle Scholar
  22. 22.
    Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer. 1999;79:1522–30.CrossRefGoogle Scholar
  23. 23.
    Schwarz RE, Harrison LE, Conlon KC, et al. The impact of splenectomy on outcomes after resection of pancreatic adenocarcinoma. J Am Coll Surg. 1999;188:516–21.CrossRefGoogle Scholar
  24. 24.
    Dai M-H, Shi N, Xing C, et al. Splenic preservation in laparoscopic distal pancreatectomy. Br J Surg. 2017;104:452–62.CrossRefGoogle Scholar
  25. 25.
    Ferrone CR, Konstantinidis IT, Sahani DV, et al. Twenty-three years of the Warshaw operation for distal pancreatectomy with preservation of the spleen. Ann Surg. 2011;253:1136–9.CrossRefGoogle Scholar
  26. 26.
    Jain G, Chakravartty S, Patel AG. Spleen-preserving distal pancreatectomy with and without splenic vessel ligation: a systematic review. HPB (Oxford). 2013;15:403–10.CrossRefGoogle Scholar
  27. 27.
    Kimura W, Inoue T, Futakawa N, et al. Spleen-preserving distal pancreatectomy with conservation of the splenic artery and vein. Surgery. 1996;120:885–90.CrossRefGoogle Scholar
  28. 28.
    Partelli S, Cirocchi R, Randolph J, et al. A systematic review and meta-analysis of spleen-preserving distal pancreatectomy with preservation or ligation of the splenic artery and vein. Surgeon. 2016;14:109–18.CrossRefGoogle Scholar
  29. 29.
    Zhou Y, Shi B, Wu L, Si X. A systematic review of radical antegrade modular pancreatosplenectomy for adenocarcinoma of the body and tail of the pancreas. HPB (Oxford). 2017;19:10–5.CrossRefGoogle Scholar
  30. 30.
    Mokdad AA, Minter RM, Zhu H, et al. Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. J Clin Oncology. 2017;35:515–22.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  • Maxime Collard
    • 1
  • Tiziana Marchese
    • 1
  • Nathalie Guedj
    • 2
    • 4
  • François Cauchy
    • 1
  • Caroline Chassaing
    • 3
  • Maxime Ronot
    • 3
    • 4
  • Safi Dokmak
    • 1
  • Olivier Soubrane
    • 1
    • 4
  • Alain Sauvanet
    • 1
    • 4
    Email author
  1. 1.Department of Hepato-Pancreatico-Biliary Surgery, Pôle des maladies de l’Appareil DigestifBeaujon Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP)ClichyFrance
  2. 2.Departments of PathologyBeaujon Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP)ClichyFrance
  3. 3.Department of RadiologyBeaujon Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP)ClichyFrance
  4. 4.Université Paris DiderotParisFrance

Personalised recommendations